- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02471911
KPT-330 Plus RICE for Relapsed/Refractory Aggressive B-Cell Lymphoma (KPT-330+RICE)
A Phase I Investigator-Initiated Study of Selinexor (KPT-330) Plus RICE in Patients With Relapsed or Refractory Aggressive B-cell Lymphomas
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Although aggressive B-cell lymphomas are potentially curable with front-line chemotherapy, at least one-third of patients experience progression or relapse. Second-line regimens such as rituximab, ifosfamide, carboplatin, and etoposide (RICE) are administered with the goal of cytoreduction prior to autologous stem cell transplantation (ASCT) in eligible patients. However, half of patients who receive salvage treatment and ASCT are still not cured.
Selinexor is a Selective Inhibitor of Nuclear Export / SINE compound, which is a new class of molecule. SINE compounds have been shown to induce apoptotic cell death in pre-clinical models of AML, CLL, T-ALL, and Ph+ ALL as well as B and T-cell non-Hodgkin lymphomas. Preliminarily, selinexor has demonstrated promising single-agent clinical activity in patients with previously treated NHL including DLBCL, warranting further investigation. Based on promising preclinical and clinical data, selinexor is currently under evaluation in combination with chemotherapy for solid tumors.
The investigators hypothesize that the combination of selinexor plus RICE will be well-tolerated and clinically active in participants with previously treated aggressive B-cell lymphomas and propose a phase I trial to evaluate this combination. Moreover, Investigators will evaluate primary patient samples before and after selinexor to investigate the mechanisms of action of selinexor, including the mechanisms by which selinexor sensitizes cells to chemotherapy, and evaluate other novel drug combinations in aggressive B-cell lymphomas.
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
New York
-
New York, New York, United States, 10021
- Weill Cornell Medical College
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Patients must have histologically confirmed aggressive B-cell non-Hodgkin lymphomas:
- DLBCL including ABC, GCB or PMBCL subtypes
- Double/triple hit lymphomas
- Indolent lymphomas transformed to aggressive lymphomas
- Follicular lymphomas grade 3B
Patients must have received at least two cycles of anthracycline based chemotherapy administered with curative intent and one of the following:
- failed to have achieve at least a partial response after 2 or more cycles
- failed to achieve a complete response after 6 or more cycles
- progressed after an initial response
- Patients must be age ≥18 years.
- Patients must have at least one site of measurable disease, 1.5 cm in diameter or greater.
- Patients must have ECOG performance status of 0-2.
Patients must have laboratory test results within these ranges:
- Absolute neutrophil count ≥ 1500/mm³
- Platelet count ≥ 100,000/mm³
- Serum creatinine clearance ≥40 mL/min
- Total bilirubin ≤ 1.5x ULN. Higher levels are acceptable if these can be attributed to active hemolysis or ineffective erythropoiesis.
- AST (SGOT) and ALT (SGPT) ≤ 2x ULN
Women of childbearing potential must agree to use dual methods of contraception and have a negative serum pregnancy test prior to selinexor treatment. Male patients must use an effective barrier method of contraception if sexually active with a female of child-bearing potential.
- Acceptable methods of contraception are condoms with contraceptive foam, oral, implantable or injectable contraceptives, contraceptive patch, intrauterine device, diaphragm with spermicidal gel, or a sexual partner who is surgically sterilized or post-menopausal.
- For both male and female patients, effective methods of contraception must be used throughout the study and for three months following the last dose.
- Patients must be able to understand and willing to sign a written informed consent document.
- Patients must be able to adhere to the study visit schedule and other protocol requirements.
- Patients must not have any serious medical condition, laboratory abnormality, or psychiatric illness that would prevent the subject from signing the informed consent form.
- Patients must not have any condition, including the presence of laboratory abnormalities, which places the subject at unacceptable risk if he/she were to participate in the study or confounds the ability to interpret data from the study.
Exclusion Criteria:
- Patients with hyperuricemia or other potential signs of tumor lysis syndrome
- Patients with more than minimally symptomatic disease (i.e. > grade 1), high tumor burden, or other indication for urgent treatment.
- Patients who have had prior malignancies (other than B-cell lymphomas) for ≤5 years with exception of currently treated basal cell, squamous cell carcinoma of the skin, or carcinoma "in situ" of the cervix or breast.
- Patients who have had other anti-cancer therapy, including radiation or experimental drug or therapy, within 28 days of enrollment.
- Patients with known HIV, active hepatitis B, active hepatitis C.
- Patients with known central nervous system involvement by lymphoma.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: All subjects
All subjects will receive KPT-330 (selinexor) on days -5 and -3 starting one week before RICE chemotherapy is started. Once chemotherapy starts, selinexor will be given on days 1, 3, and 5 of each chemotherapy cycle. RICE chemotherapy will consist of Rituximab, ifosfamide, carboplatin, etoposide, and dexamethasone. |
KPT-330 administered orally on days -5 and -3 prior to starting chemotherapy.
Once chemotherapy starts, KPT-330 will be administered on days 1, 3, and 5 of each cycle.
Dose levels will range from 20 mg to 100mg with a standard 3+3 escalation schema.
Other Names:
IV Rituximab 375 mg/m2 on D1
Other Names:
IV Etoposide 100 mg/m2 on D1-3
IV Carboplatin AUC 5 on D2
IV Ifosfamide 5 g/m2 on D2
20 mg qd on Days -5 and -3.
20 mg qd on Days 1-5
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Maximum Tolerated Dosage (MTD) of Selinexor/KPT-330 when combined with RICE chemo in a relapsed/refractory aggressive b-cell lymphoma setting.
Time Frame: approximately 24 months
|
The highest dose level at which no more than 1 or 6 patients presents with a dose-limiting toxicity (DLT) during the first 6 cycles of treatment
|
approximately 24 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Survival of subjects treated with KPT-330 + RICE
Time Frame: approximately 24 months per patient
|
Overall survival of patients enrolled on KPT-330 + RICE
|
approximately 24 months per patient
|
Progression-Free Survival of subjects treated with KPT-330 + RICE
Time Frame: approximately 24 months per patient
|
Progression-free survival of patients enrolled on KPT-330+RICE
|
approximately 24 months per patient
|
Number of patients who demonstrate a Response to KPT-330+RICE
Time Frame: approximately 24 months per patient
|
The efficacy (as assessed by clinical response) of the combination of KPT-330 + RICE in patients with Rel/Ref b-cell lymphoma
|
approximately 24 months per patient
|
Number of patients who undergo stem cell collection after induction therapy with KPT-330 + RICE
Time Frame: approximately 24 months per patient
|
The number of patients who can feasibly undergo a stem cell transplant after treatment with KPT-330+RICE
|
approximately 24 months per patient
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Behavioral Symptoms
- Immune System Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Lymphoproliferative Disorders
- Lymphatic Diseases
- Immunoproliferative Disorders
- Lymphoma, Non-Hodgkin
- Aggression
- Lymphoma
- Lymphoma, B-Cell
- Lymphoma, Large B-Cell, Diffuse
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Autonomic Agents
- Peripheral Nervous System Agents
- Enzyme Inhibitors
- Anti-Inflammatory Agents
- Antirheumatic Agents
- Antineoplastic Agents
- Immunologic Factors
- Antiemetics
- Gastrointestinal Agents
- Glucocorticoids
- Hormones
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Antineoplastic Agents, Hormonal
- Antineoplastic Agents, Alkylating
- Alkylating Agents
- Antineoplastic Agents, Phytogenic
- Topoisomerase II Inhibitors
- Topoisomerase Inhibitors
- Antineoplastic Agents, Immunological
- Dexamethasone
- Carboplatin
- Etoposide
- Ifosfamide
- Rituximab
Other Study ID Numbers
- 1502015891
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Diffuse Large B-Cell Lymphoma
-
Memorial Sloan Kettering Cancer CenterRecruitingLymphoma | Lymphoma, B-Cell | DLBCL - Diffuse Large B Cell Lymphoma | Large B-cell Lymphoma | Large-cell Lymphoma | Mediastinal B-Cell Diffuse Large Cell LymphomaUnited States
-
Roswell Park Cancer InstituteNational Cancer Institute (NCI); AmgenActive, not recruitingRecurrent Diffuse Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | CD20 Positive | Stage I Diffuse Large B-Cell Lymphoma | Stage II Diffuse Large B-Cell Lymphoma | Stage III Diffuse Large B-Cell Lymphoma | Stage IV Diffuse Large B-Cell LymphomaUnited States
-
University Hospital Southampton NHS Foundation...Hoffmann-La RocheTerminatedDiffuse Large B Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Relapsed Diffuse Large B-Cell LymphomaUnited Kingdom
-
Qian WenbinNot yet recruitingDiffuse Large B Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Relapsed Diffuse Large B-Cell LymphomaChina
-
National Cancer Institute (NCI)WithdrawnDiffuse, Large B-cell Lymphoma | Lymphoma, Diffuse Large-Cell | Lymphoma, Diffuse Large-Cell B-cell | Large-Cell Lymphoma, Diffuse
-
Dana-Farber Cancer InstituteBayer; AbbVieActive, not recruitingDiffuse Large B Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Relapsed Diffuse Large B-Cell LymphomaUnited States
-
Memorial Sloan Kettering Cancer CenterSanofi; Columbia University; Medical College of Wisconsin; University of Rochester and other collaboratorsActive, not recruitingDiffuse Large B-cell Lymphoma (DLBCL) | Relapsed Diffuse Large B-cell Lymphoma (DLBCL) | Refractory Diffuse Large B-cell Lymphoma (DLBCL)United States
-
Autolus LimitedCompletedDiffuse Large B Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | DLBCL | Relapsed Diffuse Large B-Cell LymphomaUnited States, United Kingdom
-
Herlev HospitalOdense University Hospital; Zealand University Hospital; Aarhus University Hospital and other collaboratorsCompletedDiffuse Large B-cell Lymphoma Recurrent | Diffuse Large B Cell Lymphoma | Diffuse Large B-Cell Lymphoma Cell of Origin
-
UNC Lineberger Comprehensive Cancer CenterCephalonCompletedLymphoma | Diffuse Large B-Cell Lymphoma | Lymphoma, Diffuse Large-Cell | Diffuse Large-Cell LymphomaUnited States
Clinical Trials on KPT-330
-
University of California, San FranciscoNational Cancer Institute (NCI)TerminatedPSA Progression | Metastatic Prostate Carcinoma in the Soft Tissue | Hormone-Resistant Prostate Cancer | Stage IV Prostate Adenocarcinoma AJCC v7 | Castration Levels of Testosterone | Prostate Carcinoma Metastatic in the BoneUnited States
-
Children's Oncology GroupNational Cancer Institute (NCI)Active, not recruitingMalignant Glioma | WHO Grade 3 Glioma | Refractory Lymphoma | Refractory Malignant Solid Neoplasm | Recurrent Lymphoma | Recurrent Malignant Solid Neoplasm | Refractory Primary Central Nervous System Neoplasm | Recurrent Childhood Central Nervous System Neoplasm | Recurrent Brain Neoplasm | Recurrent Childhood...United States
-
Kari KendraKaryopharm Therapeutics IncCompletedRecurrent MelanomaUnited States
-
Erin BertinoKaryopharm Therapeutics IncTerminatedRecurrent Small Cell Lung CarcinomaUnited States
-
Karyopharm Therapeutics IncTerminatedSquamous Cell CarcinomaUnited States, Canada
-
Karyopharm Therapeutics IncCompletedHematological MalignanciesUnited States, Denmark, Canada
-
Karyopharm Therapeutics IncTerminatedRichter's TransformationUnited States, Germany, United Kingdom, Spain, Poland
-
Morten Mau-SoerensenHospices Civils de Lyon; Gustave Roussy, Cancer Campus, Grand Paris; Institut... and other collaboratorsUnknownThymoma | Advanced Thymic Epithelial TumourDenmark, France
-
Karyopharm Therapeutics IncRecruitingDiffuse Large B-cell LymphomaUnited Kingdom, United States, Australia, Austria, Belgium, Bulgaria, Canada, France, Germany, Greece, Hungary, India, Israel, Italy, Netherlands, New Zealand, Poland, Serbia, Spain
-
Gabrail Cancer Center ResearchKaryopharm Therapeutics IncCompletedCarcinoma, NeuroendocrineUnited States